British National Formulary (BNF) 76

Compiled with the advice of clinical experts and continually updated to reflect the latest evidence from credible sources worldwide, the new edition of the British National Formulary 76 (BNF) provides up-to-date guidance on prescribing, dispensing, and administering medicines. Access to the latest edition of the BNF is vital for healthcare professionals, as it reflects current best practice as well as legal and professional guidelines relating to the uses of medicines.
Significant new content updates include:
Updated guidance on acute sinusitis, attentiondeficit hyperactivity disorder, chronic asthma, country recommendations formalaria prophylaxis, and cystic fibrosis.
New drug monographs including benralizumab, guselkumab, midostaurin, niraparib, ocrelizumab, tenofoviralafenamide, tivozanib, and tramadol with dexketoprofen.
New safety information about mycophenolatemofetil and mycophenolic acid with updated contraception advice for male patients,and valproate medicines now contraindicated in women and girls of childbearingpotential unless conditions of Pregnancy Prevention Programme are met.
Updated advice about alendronic acid, ibandronicacid, risedronate sodium and zoledronic acid for treating osteoporosis and raloxifenefor the primary prevention of osteoporotic fragility fractures inpostmenopausal women.
Significant dose changes including the initialdose for erectile dysfunction and neurogenic erectile dysfunction forViridal® Duo (alprostadil), bosutiniband olaparib doses in renal impairment, candesartan cilexetil clarification ofmaximum dose in heart failure, and chloroquine clarification of doseequivalence statement and dosing for rheumatoid arthritis and systemic discoidlupus erythematosus